Low‑dose Aspirin for Primary Prevention of Cardiovascular Events in Postmenopausal Women with Type‑2 Diabetes: The Prescriptive Approach in the Real World

Maria Maiello, Annagrazia Cecere, Annapaola Zito, Marco Matteo Ciccone, Pasquale Palmiero


Background: The long‑term efficacy of low‑dose aspirin for primary prevention of cardiovascular (CV) events in postmenopausal women with type‑2 diabetes is controversial. Therefore, it is recommended only on an individual basis, recommendation of grade C. Methods: We enrolled 275 consecutive postmenopausal women with type‑2 diabetes, without an increased bleeding risk and without preexisting CV disease as coronary artery disease, stroke, and peripheral vascular disease, but with a high risk assessed by score >10%, aged 60–69 years. All were receiving aspirin (75–100 mg daily), aspirin group (AG). 170 postmenopausal women with type‑2 diabetes and without preexisting cardiovascular (CV) disease, but not on aspirin treatment, despite a high risk assessed by score >10%, were control group (CG). Mean age was 66 ± 4 years for AG and 65 ± 7 years for CG. Our goal was to identify the prevalence of low‑dose aspirin prescriptions in these populations according to different clinical conditions. Results: Women with only high risk were 41/275 (15%) on AG and 72/170 (42.3%) on CG, Chi‑squared 41, Odds ratio 0.2, c.i. 95%, P < 0.0001. Women affected by metabolic syndrome were 105/275 (38.1%) on AG and 47/170 (27.6%) on CG, Chi‑squared 5.1, Odds ratio 1.6, c.i. 95%, P < 0.02. Women affected by metabolic cardiomyopathy were 111/275 (40.3%) on AG and 44/170 (25.9%) on CG, Chi‑squared 8, Odds ratio 1.8, c.i. 95%, P < 0.004. Women affected by diabetic cardiomyopathy were 18/275 (6.6%) on AG and 7/170 (4.2%) on CG, Chi‑squared 1.2, Odds ratio 16, c.i. 95%, P < 0.2 n.s. Conclusions: Low‑dose aspirin in our population is prescribed preferentially in postmenopausal women with type‑2 diabetes when affected by metabolic syndrome or metabolic cardiomyopathy, at the opposite women with only high risk have lower chance to receive aspirin.


Cardiovascular events; low‑dose aspirin; postmenopausal women; primary prevention; type‑2 diabetes

Full Text:



Haffner SM. Coronary heart disease in patients with diabetes.

N Engl J Med 2000;342:1040‑2.

Haffner SM. Epidemiology of type 2 diabetes: Risk factors.

Diabetes Care 1998;21(Suppl 3):C3‑6.

Aspirin effects on mortality and morbidity in patients with

diabetes mellitus. Early treatment diabetic retinopathy study

report 14. ETDRS investigators. JAMA 1992;268:1292‑300.

Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M,

Doi N, et al. Low‑dose aspirin for primary prevention of

atherosclerotic events in patients with type 2 diabetes:

A randomized controlled trial. JAMA 2008;300:2134‑41.

Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R,

Prescott R, et al. The prevention of progression of arterial

disease and diabetes (POPADAD) trial: Factorial randomised

placebo controlled trial of aspirin and antioxidants in patients

with diabetes and asymptomatic peripheral arterial disease. BMJ


Pignone M, Williams CD. Aspirin for primary prevention of

cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol


De Berardis G, Sacco M, Strippoli GF, Pellegrini F,

Graziano G, Tognoni G, et al. Aspirin for primary prevention of

cardiovascular events in people with diabetes: Meta‑analysis of

randomised controlled trials. BMJ 2009;339:b4531.

Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al.

Aspirin for primary prevention of cardiovascular events in

patients with diabetes: A meta‑analysis. Diabetes Res Clin Pract


Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB,

Geske JB, et al. Aspirin for the primary prevention of

cardiovascular events: A systematic review and meta‑analysis

comparing patients with and without diabetes. Diabetes Care


ASCEND Study Collaborative Group, Bowman L, Mafham M,

Wallendszus K, Stevens W, Buck G, et al. Effects of aspirin for

primary prevention in persons with diabetes mellitus. N Engl J

Med 2018;379:1529‑39.

Zheng SL, Roddick AJ. Association of aspirin use for primary

prevention with cardiovascular events and bleeding events:

A systematic review and meta‑analysis. JAMA 2019;321:277‑87.

Yerman T, Gan WQ, Sin DD. The influence of gender on the

effects of aspirin in preventing myocardial infarction. BMC Med


Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G,

Brown DL. Aspirin for the primary prevention of cardiovascular

events in women and men: A sex‑specific meta‑analysis of

randomized controlled trials. JAMA 2006;295:306‑13.

Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JF,

Roncaglioni MC, et al. Effects of aspirin on risks of vascular

events and cancer according to bodyweight and dose: Analysis of

individual patient data from randomised trials. Lancet Lond Engl


U.S. Preventive Services Task Force. Postmenopausal hormone

replacement therapy for primary prevention of chronic

conditions: Recomendations and rationale. Ann Intern Med


Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM,

Fortmann SP, et al. AHA guidelines for primary prevention of

cardiovascular disease and stroke: 2002 update: Consensus panel

guide to comprehensive risk reduction for adult patients without

coronary or other atherosclerotic vascular diseases. American

heart association science advisory and coordinating committee.

Circulation 2002;106:388‑91.

Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra‑Strobos N,

Fabunmi RP, et al. Evidence‑based guidelines for cardiovascular

disease prevention in women. Circulation 2004;109:672‑93.

Ridker PM, Cook NR, Lee I‑M, Gordon D, Gaziano JM,

Manson JE, et al. A randomized trial of low‑dose aspirin in the

primary prevention of cardiovascular disease in women. N Engl

J Med 2005;352:1293‑304.

Xie M, Shan Z, Zhang Y, Chen S, Yang W, Bao W, et al. Aspirin

for primary prevention of cardiovascular events: Meta‑analysis

of randomized controlled trials and subgroup analysis by sex and

diabetes status. PLoS One 2014;9:e90286.

Authors/Task Force Members, Piepoli MF, Hoes AW, Agewall S,

Albus C, Brotons C, et al. 2016 European Guidelines on

cardiovascular disease prevention in clinical practice: The

sixth joint task force of the european society of cardiology and

other societies on cardiovascular disease prevention in clinical

practice (constituted by representatives of 10 societies and by

invited experts): Developed with the special contribution of

the European Association for cardiovascular prevention and

rehabilitation (EACPR). Eur J Prev Cardiol 2016;23:NP1‑96.

Maiello M, Zito A, Ciccone MM, Palmiero P. Metabolic

syndrome and its components in postmenopausal women

living in southern Italy, Apulia region. Diabetes Metab Syndr


Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M,

Burnier M, et al. 2018 ESC/ESH Guidelines for the management

of arterial hypertension. Eur Heart J 2018;39:3021‑104.

Halvorsen S, Andreotti F, ten Berg JM, Cattaneo M, Coccheri S,

Marchioli R, et al. Aspirin therapy in primary cardiovascular

disease prevention: A position paper of the European society

of cardiology working group on thrombosis. J Am Coll Cardiol


Cook NR, Lee I‑M, Zhang SM, Moorthy MV, Buring JE.

Alternate‑day, low‑dose aspirin and cancer risk: Long‑term

observational follow‑up of a randomized trial. Ann Intern Med


Gum PA, Kottke‑Marchant K, Poggio ED, Gurm H, Welsh PA,

Brooks L, et al. Profile and prevalence of aspirin resistance

in patients with cardiovascular disease. Am J Cardiol


Mikkola T, Turunen P, Avela K, Orpana A, Viinikka L,

Ylikorkala O. 17 beta‑estradiol stimulates prostacyclin, but not

endothelin‑1, production in human vascular endothelial cells.

J Clin Endocrinol Metab 1995;80:1832‑6.

Arora S, Veves A, Caballaro AE, Smakowski P, LoGerfo FW.

Estrogen improves endothelial function. J Vasc Surg

;27:1141‑6; discussion 1147.

Mendelsohn ME, Karas RH. The protective effects of estrogen

on the cardiovascular system. N Engl J Med 1999;340:1801‑11.

Capodanno D, Angiolillo DJ. Impact of race and gender on

antithrombotic therapy. Thromb Haemost 2010;104:471‑84.

Ajayi AA, Mathur R, Halushka PV. Testosterone increases

human platelet thromboxane A2 receptor density and aggregation

responses. Circulation 1995;91:2742‑7.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ,

Kooperberg C, Stefanick ML, et al. Risks and benefits of

estrogen plus progestin in healthy postmenopausal women:

Principal results From the Women’s Health Initiative randomized

controlled trial. JAMA 2002;288:321‑33.

Langer RD, Pradhan AD, Lewis CE, Manson JE, Rossouw JE,

Hendrix SL, et al. Baseline associations between postmenopausal

hormone therapy and inflammatory, haemostatic, and lipid

biomarkers of coronary heart disease. The women’s health

initiative observational study. Thromb Haemost 2005;93:1108‑16.

Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR,

Lasser NL, et al. Estrogen plus progestin and the risk of coronary

heart disease. N Engl J Med 2003;349:523‑34.

Sex differences in platelet reactivity and response to low‑dose

aspirin therapy.‑PubMed‑NCBI [Internet]. [cited 2019 Mar 03].

Available from: https://www.ncbi.nlm.nih.gov/pubmed/16551714.

A sex difference in the effect of aspirin on “spontaneous” platelet

aggregation in whole blood.‑PubMed‑NCBI [Internet]. Available

from: https://www.ncbi.nlm.nih.gov/pubmed/?term=A+sex+diffe



aemost++1983%3B50%3A773%E2%80%93774. [Last cited on

Mar 03].

Profile and prevalence of aspirin resistance in patients with

cardiovascular disease.‑PubMed‑NCBI [Internet]. Available

from: https://www.ncbi.nlm.nih.gov/pubmed/11472699. [Last

cited on 2019 Mar 03].

Sex difference in the antiplatelet effect of aspirin in patients

with stroke.‑PubMed‑NCBI [Internet]. Available from: https://





%E2%80%93817. [Last cited on 2019 Mar 03].

Ye X, Fu J, Yang Y, Gao Y, Liu L, Chen S. Frequency‑risk

and duration‑risk relationships between aspirin use and gastric

cancer: A systematic review and meta‑analysis. PloS One


Cao Y, Nishihara R, Wu K, Wang M, Ogino S, Willett WC, et al.

Population‑wide impact of long‑term use of aspirin and the risk

for cancer. JAMA Oncol 2016;2:762‑9.

Maas AH, Appelman YE. Gender differences in coronary heart

disease. Neth Heart J 2010;18:598‑602.

Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S,

Kandala NB, et al. Aspirin for prophylactic use in the primary

prevention of cardiovascular disease and cancer: A systematic

review and overview of reviews. Health Technol Assess Winch

Engl 2013;17:1‑253.

Sanchis‑Gomar F, Perez‑Quilis C, Leischik R, Lucia A.

Epidemiology of coronary heart disease and acute coronary

syndrome. Ann Transl Med 2016;4:256.